ABSCI CORP. DL -,0001 Aktie

Absci reports positive interim results from the Phase 1 HEADLINE study for the hair‑loss candidate ABS‑201 without serious adverse events, which led to a sharp share‑price rise on June 24. At the same time, the company agreed a $100 million equity placement involving a pharmaceutical company. The funds are intended to support further development of the antibody therapy. » Więcej na finanzen.net

Absci is gaining investor attention after its AI-designed antibody ABS-201 moved into human clinical testing for androgenetic alopecia, with early safety data from the HEADLINE trial supporting the program. The company highlights its generative AI platform as a driver to accelerate antibody discovery and reduce development costs, with potential applications beyond hair loss including endometriosis. Hedge fund holdings in Absci rose modestly quarter-over-quarter, and bullish commentary frames the stock as benefiting from broader adoption of AI-enabled drug discovery if clinical progress continues. » Więcej na finance.yahoo.com

Absci reported revenue of $215,000 for Q1 2026 versus expected $1.43 million, a negative surprise of 84.97%. Earnings per share of -$0.19 were slightly better than the expectation of -$0.1943. R&D expenses rose 17.7% to $19.3 million; cash stood at $125.7 million and is expected to fund operations into the first half of 2028. Management is focusing on the ABS-201 program, with preliminary proof-of-concept data in H2 2026 and full data in early 2027; the stock reacted only moderately to the results. » Więcej na de.investing.com